Letters to the Editor

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Haematologica Early view Dec 7, 2022 https://doi.org/10.3324/haematol.2022.282031